表紙
市場調査レポート

Celldex Therapeutics, Inc.の製品パイプライン分析

Celldex Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 240913
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
Celldex Therapeutics, Inc.の製品パイプライン分析 Celldex Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年05月29日 ページ情報: 英文 51 Pages
概要

Celldex Therapeutics, Inc.は、癌、感染症および炎症性疾患向けのワクチンや標的免疫療法技術を開発するバイオ医薬品企業です。

当レポートでは、Celldex Therapeutics, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Celldex Therapeutics, Inc.の基本情報

Celldex Therapeutics, Inc.の概要

  • 主要情報
  • 企業情報

Celldex Therapeutics, Inc.:R&Dの概要

  • 主な治療範囲

Celldex Therapeutics, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Celldex Therapeutics, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Celldex Therapeutics, Inc.:薬剤プロファイル

  • glembatumumab vedotin
  • rindopepimut
  • CDX-1401
  • CDX-301
  • CDX-2401
  • varlilumab
  • CDX-014
  • CDX-1189

Celldex Therapeutics, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Celldex Therapeutics, Inc.:最近のパイプライン動向

Celldex Therapeutics, Inc.:休止中のプロジェクト

Celldex Therapeutics, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • CDX-1135

Celldex Therapeutics, Inc.:企業発表

Celldex Therapeutics, Inc.:本社と子会社の所在地

Celldex Therapeutics, Inc.:主要製造設備

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07101CDB

Summary

Global Markets Direct's, 'Celldex Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Celldex Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celldex Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Celldex Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Celldex Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Celldex Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Celldex Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Celldex Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Celldex Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Celldex Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celldex Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Celldex Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celldex Therapeutics, Inc. Snapshot
    • Celldex Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Celldex Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Celldex Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Celldex Therapeutics, Inc. - Pipeline Products Glance
    • Celldex Therapeutics, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Celldex Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Celldex Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Celldex Therapeutics, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Celldex Therapeutics, Inc. - Drug Profiles
    • rindopepimut
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-1401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glembatumumab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • varlilumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-1135
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-2401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-014
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Celldex Therapeutics, Inc. - Pipeline Analysis
    • Celldex Therapeutics, Inc. - Pipeline Products by Target
    • Celldex Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Celldex Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Celldex Therapeutics, Inc. - Recent Pipeline Updates
  • Celldex Therapeutics, Inc. - Dormant Projects
  • Celldex Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CDX-1135
  • Celldex Therapeutics, Inc. - Company Statement
  • Celldex Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Celldex Therapeutics, Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celldex Therapeutics, Inc., Key Information
  • Celldex Therapeutics, Inc., Key Facts
  • Celldex Therapeutics, Inc. - Pipeline by Indication, 2015
  • Celldex Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Celldex Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Celldex Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Celldex Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Celldex Therapeutics, Inc. - Phase III, 2015
  • Celldex Therapeutics, Inc. - Phase II, 2015
  • Celldex Therapeutics, Inc. - Phase I, 2015
  • Celldex Therapeutics, Inc. - Preclinical, 2015
  • Celldex Therapeutics, Inc. - Unknown, 2015
  • Celldex Therapeutics, Inc. - Pipeline by Target, 2015
  • Celldex Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Celldex Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Celldex Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Celldex Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Celldex Therapeutics, Inc. - Discontinued Pipeline Products, 2015
  • Celldex Therapeutics, Inc., Other Locations
  • Celldex Therapeutics, Inc., Key Manufacturing Facilities

List of Figures

  • Celldex Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Celldex Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Celldex Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Celldex Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Celldex Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Celldex Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top